Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SFRP1 | Q8N474 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101626 | 0.94 | SFRP1 (0.89) | SFRP1HTTALDH1A1POLBLMNA | |
| SCHEMBL4618738 | 0.94 | SFRP1 (0.89) | SFRP1HTTALDH1A1POLBLMNA | |
| SCHEMBL4618123 | 0.91 | SFRP1 (0.84) | SFRP1HTTALDH1A1POLBLMNA | |
| SCHEMBL4617339 | 0.88 | SFRP1 (0.79) | SFRP1HTTALDH1A1POLBLMNA | |
| SCHEMBL6104071 | 0.87 | HTT (0.81) | SFRP1HTTALDH1A1POLBLMNA | |
| SCHEMBL6102308 | 0.87 | SFRP1 (0.76) | SFRP1HTTALDH1A1POLBLMNA | |
| SCHEMBL6101694 | 0.87 | SFRP1 (0.76) | SFRP1HTTALDH1A1POLBLMNA | |
| SCHEMBL4616812 | 0.86 | SFRP1 (0.76) | SFRP1HTTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4616978 | 0.85 | SFRP1 (0.75) | SFRP1HTTALDH1A1POLB | |
| SCHEMBL4619589 | 0.85 | SFRP1 (0.74) | SFRP1HTTALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200355674-A1 | HUMAN IPSC-BASED DRUG TESTING PLATFORM FOR MUSCULAR DYSTROPHY | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-11-12 | — | — | US | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-12169196-B2 | Human iPSC-based drug testing platform for muscular dystrophy | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-12-17 | — | — | US | disclosed |
| US-20200355674-A1 | HUMAN IPSC-BASED DRUG TESTING PLATFORM FOR MUSCULAR DYSTROPHY | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | SFRP1 1/4885HTT 4703/4885ALDH1A1 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.